ReviewImmunologic research2013
Pharmacogenetics and pharmacogenomics in rheumatology.
Review in Immunologic research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The genetic puzzle of rheumatoid arthritis: Causes, progression, and treatment.Biochemistry and biophysics reports · 2025Review
- Pharmacogenomics of Methotrexate Pathway in Rheumatoid Arthritis Patients: Approach toward Personalized Medicine.Diagnostics (Basel, Switzerland) · 2022Article
- Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.The pharmacogenomics journal · 2021Article
- Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.Arthritis research & therapy · 2019Article
- Genetic and environmental risk factors for rheumatoid arthritis.Best practice & research. Clinical rheumatology · 2017Review
- Effect of Fcγ-receptor 3a (RMD open · 2017Article
- Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.BMC genetics · 2016Article
- Pharmacogenetics of treatment response in psoriatic arthritis.Current rheumatology reports · 2015Review
- Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.BMC genetics · 2015Article
- Management of juvenile idiopathic arthritis: hitting the target.Nature reviews. Rheumatology · 2015Review
- Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.Immunologic research · 2013Article
- Personalized medicine in rheumatology.ReumatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.